Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors with Substantial Losses to Contact the Firm Pharmaceutical Investing
Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer Pharmaceutical Investing
Bristol Myers Squibb Withdraws Supplemental Biologics License Application for Reblozyl® for Non-transfusion Dependent Beta Thalassemia Pharmaceutical Investing
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity Pharmaceutical Investing
Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System Pharmaceutical Investing
Knight to Present at the Jefferies 2022 Healthcare Conference in New York City Pharmaceutical Investing
Aurinia Presents Data Demonstrating LUPKYNIS® is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Pharmaceutical Investing
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Pharmaceutical Investing
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia Improved Survival in People Hospitalized with COVID-19 Pharmaceutical Investing